No Data
No Data
No Data
CICC: Maintains a 'outperform' rating on Akeso (09926) with the target price raised to HK$90.
Akeso's new drug Yixining (Inoliximab, PCSK9) has applied for marketing approval and has been approved by the China National Medical Products Administration.
Hong Kong stocks moving abnormally | Akeso (09926) surged over 3% in the morning, proposing to issue approximately 4.99% discounted for a total of 31.7 million shares for the research and development of biopharmaceutical products.
Akeso (09926) rose more than 3% in the morning, as of the deadline, up 2.71% to HK$66.25, with a turnover of HK$1.069 billion.
Morgan Stanley Acting as Placing Agents for Akeso
Akeso to Use Placement Proceeds for R&D of Biopharmaceutical Products
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Akeso, Inc. Aims to Raise HK$1.94 Billion in Share Placement
No Data
No Data
MayFlower : It was predictable..
Midnite52 : yep